It was reported yesterday that Germany-based Boehringer Ingelheim has extended its collaboration with the University of Dundee to develop new medicines that target and destroy cancer causing proteins.
The agreement partners Professor Alessio Ciulli, one of the pioneers in the field of Proteolysis targeting chimeras, based in the School of Life Sciences at Dundee, with Boehringer Ingelheim's pharmaceutical expertise.
Darryl B. McConnell, PhD, Senior Vice President and Research Site Head, Boehringer Ingelheim, Vienna, Austria, said, 'PROTACs are a disruptive therapeutic modality which are bringing previously deemed undruggable targets within reach. Our collaboration will continue to work to bring this new class of medicines to patients. The joint team is making rapid progress and have successfully reached the first collaboration milestone setting a solid basis for achieving our goals.'
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886